ArticleMolecular cancer therapeutics2021
Datopotamab Deruxtecan, a Novel TROP2-directed Antibody-drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells.
Article in Molecular cancer therapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 194 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
194 citing papers in PubMed, 2 syntheses or guidelines pooled it, 265 citations in OpenAlex.
- Datopotamab deruxtecan in breast cancer treatment: a systematic review of clinical efficacy and safety.Frontiers in immunology · 2026Pooled it
- The efficacy and safety of datopotamab deruxtecan (Dato-DXd) in advanced solid tumors: a systematic review and meta-analysis.European journal of medical research · 2025Pooled it
- TROPION-Urothelial03: a phase II/III study of datopotamab deruxtecan (Dato-DXd) for locally advanced or metastatic urothelial carcinoma.Future oncology (London, England) · 2026Trial
- FDA Approval Summary: Datopotamab Deruxtecan-dlnk for Treatment of Patients with Unresectable or Metastatic, HR-Positive, HER2-Negative Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Trial
- Perioperative durvalumab plus chemotherapy plus new agents for resectable non-small-cell lung cancer: the platform phase 2 NeoCOAST-2 trial.Nature medicine · 2025Trial
- Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Trial
- Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025Trial
- Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.Nature medicine · 2024Trial
- Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial.Nature medicine · 2024Trial
- Antibody-drug conjugates in breast cancer: redefining targeted therapy.The Journal of clinical investigation · 2026Review
- Quantitative Systems Pharmacology Model for TROP-2 Targeted Antibody-Drug Conjugate in Triple-Negative Breast Cancer.bioRxiv : the preprint server for biology · 2026Article
- Exatecan-Loaded HSA Nanoparticles for Sustained Release and Enhanced Cancer Treatment.ACS omega · 2026Article
- Exposure-Response Analyses of Datopotamab Deruxtecan (Dato-DXd), a TROP2-Directed Antibody-Drug Conjugate, in Advanced Non-small Cell Lung Cancer.Clinical pharmacology and therapeutics · 2026Article
- Neoadjuvant therapy for stage II-III triple-negative breast cancer: Current evidence, clinical boundaries and emerging strategies (Review).Oncology letters · 2026Review
- Enhancing the efficacy of B7-H3-targeting antibody-drug conjugate DS-7300a in TP53-deficient tumors by inducing ferroptosis.Oncogene · 2026Article
- Activity of datopotamab deruxtecan in TROP2-expressing low-grade serous ovarian cancer: a preclinical study.Gynecologic oncology reports · 2026Article
- Datopotamab deruxtecan for endocrine-resistant HR-positive/HER2-negative breast cancer: biological rationale and clinical evidence.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Pathophysiological and Molecular Features of DXd ADC-Related Interstitial Pneumonitis in Cynomolgus Monkeys.Cancer science · 2026Article
- Trophoblast cell-surface antigen 2-targeted "sacituzumab tirumotecan": a new approach for epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small cell lung cancer.Translational lung cancer research · 2026Article
- Antibody-Drug Conjugates Targeting HER2 and Trop-2: A New Force in Precision Treatment for Solid Tumors.Pharmaceuticals (Basel, Switzerland) · 2026Review
134 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Trophoblast cell surface antigen 2 (TROP2) is highly expressed on various epithelial tumors and correlates with poor prognosis. We developed the novel TROP2-directed antibody-drug conjugate (ADC), datopotamab deruxtecan (Dato-DXd, DS-1062a), with a potent DNA topoisomerase I inhibitor (DXd), and evaluated its antitumor activity and safety profiles in preclinical models.The pharmacologic activity and mechanism of action of Dato-DXd were investigated in several human cancer cell lines and xenograft mouse models including patient-derived xenograft (PDX) models. Safety profiles were also assessed in rats and cynomolgus monkeys.Dato-DXd bound specifically to TROP2 and was internalized into tumor cells followed by intracellular trafficking to lysosome and DXd release, which induced DNA damage and apoptosis in TROP2-expressing tumor cells
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.